

ARENA PHARMACEUTICALS INC

Form 8-K

February 03, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 8-K**

**Current Report Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 1, 2006**

---

**Arena Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**23-2908305**

(Commission File Number)

**000-31161**

(I.R.S. Employer  
Identification No.)

**6166 Nancy Ridge Drive, San Diego California**

(Address of principal executive offices)

**92121**

(Zip Code)

Registrant's telephone number, including area code: **(858) 453-7200**

**Not Applicable.**

(Former name or former address, if changed since last report.)

## Edgar Filing: ARENA PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01**

**Other Events.**

On February 2, 2006, Arena Pharmaceuticals, Inc. (the Company ) announced that the underwriters have exercised an over-allotment option to purchase an additional 885,016 shares of its common stock in connection with its follow-on stock offering that priced on January 26, 2006. Including the over-allotment shares being purchased, the offering will total 10,637,524 shares at a public offering price of \$16.90 per share. After deducting the underwriting discounts and commissions and other expenses of the offering, the Company expects the proceeds of the offering to be approximately \$169.0 million.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ARENA PHARMACEUTICALS, INC.**

Dated: February 2, 2006

By: /s/ Steven W. Spector  
Steven W. Spector,  
*Senior Vice President, General Counsel and Secretary*